Olema Pharmaceuticals financials
$8.54−0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$178.7M | -$142.3M | -$105.0M | -$107.0M | -$71.5M | -$21.5M |
| Net income | -$162.5M | -$129.5M | -$96.7M | -$104.8M | -$71.1M | -$24.0M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-1.87 | $-2.20 | $-2.14 | $-2.62 | $-1.80 | $-3.42 |
| EBITDA | -$178.2M | -$141.9M | -$104.6M | -$105.3M | -$71.3M | -$21.5M |
| Operating cash flow | -$146.7M | -$104.4M | -$83.7M | -$82.1M | -$50.7M | -$19.9M |
| Free cash flow | -$146.7M | -$104.5M | -$83.7M | -$82.4M | -$52.3M | -$19.9M |
| Diluted shares | 87.0M | 58.7M | 45.2M | 40.0M | 39.5M | 7.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $48.3M | $139.5M | $68.5M | $23.7M | $13.8M | $338.5M |
| Short-term investments | $457.1M | $294.6M | $193.3M | $180.7M | $273.4M | — |
| Total debt | $3.0M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $533.4M | $451.0M | $276.9M | $215.6M | $295.9M | $342.7M |
| Total liabilities | $54.9M | $42.0M | $23.1M | $18.1M | $11.4M | $4.6M |
| Shareholders' equity | $478.6M | $409.0M | $253.9M | $197.5M | $284.6M | $338.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology